IRF1 and malignant colon neoplasm: Interferon-receptor–associated Janus kinase 2 (JAK2) was also highly expressed in MSI subtype colon cancer patients (Fig. 2c), suggesting the activation of IFN-γ-JAK2-IRF1 axis.